Newsroom
The Latest News From the Ivy Center
The Ivy Brain Tumor Center at Barrow Neurological Institute strives to be a valuable resource for any brain tumor or brain cancer-related media needs. Our media relations team is happy to help answer questions and arrange interviews. The expert neurosurgeons, neuro-oncologists and scientists at the Ivy Center are available to speak on a variety of topics.
Our state-of-the-art media studio is available for audio and video interviews. We can also arrange filming opportunities at various locations around the center and labs.
To contact the media relation team, call 602-406-7437 or email: [email protected].
Please see below for the latest media coverage and news from the Ivy Center. To read about our inspiring patients and those behind the scenes at the Ivy Center, visit the Ivy Blog.
AstraZeneca’s ‘radiosensitizer’ may enhance efficacy of radiation for deadly brain cancer: #AACR24
Endpoints News highlighted Dr. Nader Sanai’s groundbreaking research with AstraZeneca's AZD1390 in glioblastoma treatment at AACR 2024. The Phase 0 study, led by Dr. Sanai, Director of the Ivy Brain Tumor Center, demonstrates the drug's efficacy in penetrating brain tissue—a pivotal advancement in glioblastoma therapy. Learn more!
AACR Annual Meeting 2024: The key announcements you need to read
Biopharma Reporter featured the Ivy Brain Tumor Center's presentation at the AACR Annual Meeting 2024, where groundbreaking advancements in glioblastoma research were highlighted. The Ivy Center unveiled promising results from their clinical trials, particularly the potential of AZD1390 as an effective radiosensitizer for treating recurrent glioblastoma.
Ivy Brain Tumor Center Announces Promising Results of Phase 0/1 Glioblastoma Study at the American Association for Cancer Research Annual Meeting
The Ivy Brain Tumor Center announced initial results from a Phase 0/1b clinical trial of AZD1390, in combination with radiation therapy, in newly diagnosed, MGMT-unmethylated glioblastoma. Results from this study will be presented at the American Association for Cancer Research Annual Meeting and demonstrate that AZD1390 may be a potent radiosensitizer in both newly diagnosed and recurrent glioblastoma patients. Read the press release to learn more.
Ivy Brain Tumor Center Announces Promising Results of Phase 0/1 Glioblastoma Study at the American Association for Cancer Research Annual Meeting
AZBio spotlighted Dr. Nader Sanai's presentation at the American Association for Cancer Research Annual Meeting, where the Ivy Brain Tumor Center revealed promising results from a Phase 0/1b clinical trial of AZD1390 combined with radiation therapy for newly diagnosed, MGMT-unmethylated glioblastoma. These findings indicate that AZD1390, an ATM kinase inhibitor, enhances radiation therapy by preventing acute DNA damage repair. Read the full story!
Ivy Brain Tumor Center Awarded U.S. Department of Defense Grant to Advance Promising Glioblastoma Drug Candidate
The Ivy Brain Tumor Center received a $1.48 million, three-year U.S. Department of Defense (DoD) Impact Award to advance the development of MnP3. This novel redox-active agent shows potential in the treatment of glioblastoma. Successful completion of the project will have a significant impact on translating the drug to clinical use.
Bringing Empathy to Brain Surgery
The Working Mom Hour Podcast featured Dr. Charuta Furey, a neurosurgery resident at Barrow Neurological Institute and the Ivy Brain Tumor Center. From navigating tough conversations with families to balancing the demands of her career with motherhood, Dr. Furey's insights offer invaluable guidance. She dives into the significance of empathy in patient care and the importance of preparation for surgery and provides practical strategies for both medical professionals and patients alike. Listen now!
Michelle Palacino featured on Rare Enough Podcast
Michelle Palacino, a dedicated caregiver in the brain tumor community and an employee at the Ivy Brain Tumor Center, was recently featured on the "Rare Enough" podcast, hosted by DJ Stewart for Head for the Cure. In this episode, Michelle discusses her personal experiences and the challenges she faces, highlighting her steadfast commitment to combating brain cancer.
Two female neuro-oncologists strive to develop new therapies for aggressive brain tumors
Featured in Women in Onc on Healio, Dr. Kelly Braun and Dr. Yoshie Umemura of the Ivy Brain Tumor Center at Barrow Neurological Institute are at the forefront of developing new treatments for aggressive brain tumors, such as glioblastoma. Their focus on translational clinical research strives to rapidly convert laboratory breakthroughs into clinical applications. They share insights on mentorship, teamwork, and the crucial balance between professional duties and personal life, providing invaluable guidance for women aspiring to leadership roles in oncology.
Ivy Brain Tumor Center Announces Promising Data for Niraparib in Phase 0/2 Glioblastoma Clinical Trial
The Ivy Brain Tumor Center at Barrow Neurological Institute announces promising results from a collaborative Phase 0/2 trial of niraparib, supported by GSK, in patients with newly diagnosed glioblastoma with unmethylated MGMT.
Ivy Center Announces First Patient Treated in Targeted Phase 0/1 Clinical Trial for High-Grade Glioma
The Ivy Brain Tumor Center announced the first patient has been treated in a novel Phase 0/1 clinical trial of BDTX-1535, an experimental drug targeting oncogenic EGFR (epidermal growth factor receptor) mutations in patients with recurrent high-grade glioma.